Treatment-resistant depression

Psychiatrist with patient
#Depression #Psychedelics #Treatment-resistant depression

Psychedelic drug could help treat depression 

The psychedelic drug dimethyltryptamine (DMT) could help treat depression when combined with psychotherapy, The Guardian has reported.  According to preliminary results reported in Nature Medicine, a trial involving 34 patients found that psychotherapy combined with DMT caused a reduction in depressive symptoms, even after the… Read More

#News

Patient speaking to psychiatrist
#Clinical trial #Treatment-resistant depression

Positive data announced for treatment-resistant depression drug 

Biopharmaceutical company AtaiBeckley has released positive topline data from the Phase IIb trial of BPL-003 in patients with treatment-resistant depression (TRD).  In the open-label study, BPL-003 met response and remission criteria for depression, with clinically meaningful antidepressant effects sustained up to eight weeks. Patients receiving an 8mg… Read More

#News

#Clinical trial #Treatment-resistant depression

Positive data published on BPL-003 for patients with TRD

Biopharmaceutical company atai Life Sciences has announced positive data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).  The open-label Phase IIa study (NCT05660642) enrolled 13 patients with TRD who were not on… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Depression #Drug repurposing #Parkinson's #Psychiatry #Treatment-resistant depression #University of Oxford

Dopamine-boosting Parkinson’s drug treats depression

A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.  In the largest clinical trial to date, pramipexole was found to be substantially more effective than a… Read More

#Editor's Choice #News

Magic Mushrooms in laboratory. Psilocybin science and research.
#Depression #Plant-based #Psilocybin #Psychedelics #Treatment-resistant depression

Where is the promise for plant-based medicines? Part 2: Psilocybin 

In the second part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of psilocybin in drug discovery. The first part explored medical cannabis.  What is the regulatory landscape of psilocybin?  Psilocybin is a naturally occurring psychedelic compound that is produced by more than… Read More

#Business & Investment #Exclusive Content #Regulatory

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News

5-Methoxy-N, N-Dimethyltryptamine
#Phase I trial #Psychedelics #Psychiatry #Treatment-resistant depression

Synthetic psychedelic successfully completes Phase I study 

Beckley Psytech has completed its Phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT).  The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants.  Initial… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Magic mushrooms
#Depression #Mental health #Psilocybin #Psychedelics #The New England Journal of Medicine #Treatment-resistant depression #Trial data

Study shows ‘magic mushrooms’ could treat depression 

Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind.  The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More

#News #Trending News